ArticleCurrent microbiology2025
Therapeutic Potential of Salvianolic Acid B Produced by Streptomyces sp. M4 Against Multi-drug-Resistant Human Pathogens.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multidrug-resistant bacteria (MDR bacteria), known as superbugs, has become a global issue responsible for lethal infections and high mortality rate. In the search for novel antimicrobial drugs, natural resources have been considered as the potent source of bioactive compounds to control infectious diseases. Microorganisms, especially actinobacteria have shown a positive impact on human health and can produce potent antimicrobial compounds with various bioactivities. In the present investigation, the antibacterial and cytotoxic properties of ethyl acetate (EtOAc) extract and salvianolic acid B from Streptomyces sp. M4 were evaluated. The EtOAc extract and salvianolic acid B displayed antibacterial activity against Bacillus subtilis, Klebsiella pneumoniae sub sp. pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), Escherichia coli S1LF and Enterobacter aerogenes with inhibition zones in the range of 14-20 mm and minimum inhibitory concentrations (MIC values) in the range of 7.80-62.25 μg/mL. The DNA nicking assay revealed that salvianolic acid B as well as EtOAc extract provided protection to pBR 322 super coiled DNA from negative effects of free radicals produced by Fenton's reagent. In vitro cytotoxicity assay demonstrated significant cytotoxic activity, with 72.62% and 68.42% inhibition against MG63 osteosarcoma cell line by the salvianolic acid B and EtOAc extract, respectively, at concentration of 5 µM. Salvianolic acid B also exhibited potent activity against drug-resistant bacteria, particularly MRSA and VRE, which are resistant to the standard antibiotics methicillin and vancomycin, respectively. To our best knowledge, this is the first report on antibacterial potential of salvianolic acid B produced by Streptomyces sp. M4 against VRE.
Indexed as
Identifiers
40679637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.